Prix Swedish Orphan Biovitrum AB (publ) (BIOVF)

Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. The company is headquartered in Stockholm, Stockholm and currently employs 1,890 full-time employees. The company went IPO on 2006-09-15. The firm develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The firm has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.